

**Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. What is the objective response rate in the small cell lung cancer cohort of the Phase I/II DS7300-A-J101 trial evaluating ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate (ADC)?**
  - 0%
  - 9%
  - 18%
  - 52%
- 2. There is currently an ongoing Phase II clinical trial evaluating I-DXd for what disease state?**
  - Multiple myeloma
  - Pancreatic cancer
  - Small cell lung cancer
  - Acute myeloid leukemia
  - Diffuse large B-cell lymphoma
- 3. The Phase III IDEate-2 trial in relapsed small cell lung cancer will evaluate I-DXd versus what active comparator arm?**
  - Pembrolizumab monotherapy
  - Atezolizumab with platinum-based chemotherapy
  - Topotecan, lurbinectedin or amrubicin
  - There is no active comparator arm
- 4. Vobramitamab duocarmazine, a novel B7-H3-targeting ADC, will be evaluated in the Phase II TAMARACK study for what disease state?**
  - Hodgkin lymphoma
  - Metastatic castration-resistant prostate cancer
  - Non-small cell lung cancer
  - Chronic lymphocytic leukemia
  - Hepatocellular carcinoma
- 5. In a Phase I study of HS-20093, a novel B7-H3-targeting ADC, what was the median progression-free survival in the small cell lung cancer cohort?**
  - 1.5 months
  - 4.7 months
  - 12.1 months
  - 18.3 months